Epidemiology, risk factors, and treatment of chronic migraine: A focus on topiramate

被引：31

作者：

Silberstein, Stephen ^{[1
]}

Diener, Hans-Christoph ^{[2
]}

Lipton, Richard ^{[3
]}

Goadsby, Peter ^{[4
]}

Dodick, David ^{[5
]}

Bussone, Genaro ^{[6
]}

Freitag, Fred ^{[8
]}

Schwalen, Susan ^{[7
]}

Ascher, Steven ^{[9
]}

Morein, Jacqueline ^{[9
]}

Greenberg, Steven ^{[10
]}

Biondi, David ^{[9
]}

Hulihan, Joseph ^{[9
]}

机构：

[1] Thomas Jefferson Univ, Jefferson Headache Ctr, Philadelphia, PA 19107 USA

[2] Univ Duisberg Essen, Dept Neurol, Essen, Germany

[3] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA

[4] Inst Neurol, Headache Grp, London WC1N 3BG, England

[5] Mayo Clin, Dept Neurol, Scottsdale, AZ USA

[6] Ist Neurochirurg C Besta, Dept Neurol, I-20133 Milan, Italy

[7] Jansen Cilag GmbH, Neuss, Germany

[8] Diamond Headache Clin Ltd, Chicago, IL USA

[9] Ortho McNeil Janssen Sci Affairs LLC, Titusville, NJ USA

[10] EMD Serono Inc, Rockland, MA USA

来源：

HEADACHE | 2008年 / 48卷 / 07期

关键词：

chronic migraine; topiramate;

D O I：

10.1111/j.1526-4610.2008.01185.x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The term chronic daily headache refers to a heterogeneous group of headache disorders characterized by a frequency of headaches on >= 15 days per month. Chronic migraine is a subtype of chronic daily headache. The prevalence of chronic migraine is similar to 1%. Baseline attack frequency and acute medication overuse have been identified as potential risk factors for the progression of migraine from an episodic disorder to a chronic condition. There is an unmet patient need for effective and safe treatments for patients with chronic migraine, but data from rigorous controlled trials are limited. Previous studies have demonstrated that topiramate is an effective and safe preventive treatment for episodic migraine. In addition, pilot studies have suggested the utility of topiramate for the prevention of chronic migraine. Two randomized, double-blind, placebo-controlled, multicenter trials investigating the efficacy and safety of topiramate in the treatment of patients with chronic migraine have recently been completed. This review presents comparative data from these 2 clinical trials, which suggest that topiramate at a dose of 100 mg daily is effective and generally well tolerated in chronic migraine.

引用

页码：1087 / 1095

页数：9

共 61 条

[1] Topiramate inhibits trigeminovascular activation: an intravital microscopy study [J].